AbbVie Inc. (ABBV) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - General
Sell if holding. At $209.51, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.7%; Concentration risk — Customer: McKesson, Cardinal Health, Cencora.
AbbVie is a diversified biopharmaceutical company with marketed products spanning immunology (Skyrizi, Rinvoq, Humira), neuroscience (Vraylar, Botox Therapeutic), oncology, and aesthetics sold globally. Skyrizi and Rinvoq together represented approximately 42% of total net... Read more
Sell if holding. At $209.51, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.7%; Concentration risk — Customer: McKesson, Cardinal Health, Cencora. Chart setup: Death cross but MACD improving, RSI 66. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — AbbVie Inc.
Latest news
- AbbVie (NYSE:ABBV) Stock Price Down 2.3% - Should You Sell? - MarketBeat — MarketBeat negative
- AbbVie (ABBV) Stock Jumps On $1.4 Billion North Carolina Campus Announcement - MEXC — MEXC positive
- AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - PR Newswire — PR Newswire positive
- AbbVie Inc. (ABBV) is attracting investor attention: Here is what you should know - MSN — MSN positive
- Kingswood Wealth Advisors LLC Raises Stock Holdings in AbbVie Inc. $ABBV - MarketBeat — MarketBeat neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerMcKesson, Cardinal Health, Cencora10-K Item 1: 'three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.) accounted for substantially all of AbbVie's pharmaceutical product sales in the United States'
- MEDIUMProductSkyrizi and Rinvoq42%10-K Item 1A: 'Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $209.51, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 8.7%; Concentration risk — Customer: McKesson, Cardinal Health, Cencora. Chart setup: Death cross but MACD improving, RSI 66. Prior stop was $197.84. Score 5.3/10, moderate confidence.
Take-profit target: $227.61 (+8.7% upside). Prior stop was $197.84. Stop-loss: $197.84.
Concentration risk — Customer: McKesson, Cardinal Health, Cencora; Thin upside margin: 8.7%; Consecutive earnings misses (3).
AbbVie Inc. trades at a P/E of 103.1 (forward 13.0). TrendMatrix value score: 6.1/10. Verdict: Sell.
40 analysts cover ABBV with a consensus score of 4.0/5. Average price target: $253.
What does AbbVie Inc. do?AbbVie is a diversified biopharmaceutical company with marketed products spanning immunology (Skyrizi, Rinvoq, Humira),...
AbbVie is a diversified biopharmaceutical company with marketed products spanning immunology (Skyrizi, Rinvoq, Humira), neuroscience (Vraylar, Botox Therapeutic), oncology, and aesthetics sold globally. Skyrizi and Rinvoq together represented approximately 42% of total net revenues in 2025, with three wholesale distributors accounting for substantially all U.S. pharmaceutical product sales.